Who
Coleen Glessner
EVP, Quality & Ethics, and CPL
Company insider
Files Form 4 as: EVP, Quality & Ethics, and CPL, Emergent BioSolutions.
In numbers
- Trades disclosed
- 39
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $306K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 8 Apr 2022
- Last trade
- 8 Jun 2026
- Last filed
- 10 Jun 2026
Companies traded
Activity over time
1 Oct 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Jun 2026filed 10 Jun 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $16K2,018 at $8.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $16K2,018 at $8.00 | filing |
| 29 Apr 2026filed 1 May 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —100,111 at $0.00 | filing |
| 29 Apr 2026filed 1 May 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —100,111 at $0.00 | filing |
| 5 Mar 2026filed 5 Mar 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $69K8,199 at $8.44 | filing |
| 5 Mar 2026filed 5 Mar 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $69K8,199 at $8.44 | filing |
| 3 Mar 2026filed 5 Mar 2026 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,834 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,834 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $2,551313 at $8.15 | filing |
| 1 Mar 2026filed 3 Mar 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $2,551313 at $8.15 | filing |
| 6 Feb 2026filed 10 Feb 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code D | $315K28,847 at $10.92 | filing |
| 6 Feb 2026filed 10 Feb 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $31K2,852 at $10.92 | filing |
| 6 Feb 2026filed 10 Feb 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code D | $315K28,847 at $10.92 | filing |
| 6 Feb 2026filed 10 Feb 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $31K2,852 at $10.92 | filing |
| 7 Oct 2025filed 16 Oct 2025 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $306K30,608 at $10.00 | filing |
| 8 Jun 2025filed 10 Jun 2025 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $8,2811,249 at $6.63 | filing |
| 7 Apr 2025filed 9 Apr 2025 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $2,131480 at $4.44 | filing |
| 6 Mar 2025filed 10 Mar 2025 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
| 6 Mar 2025filed 10 Mar 2025 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
| 1 Mar 2025filed 4 Mar 2025 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $2,341313 at $7.48 | filing |
News
Comparing Monte Rosa Therapeutics (NASDAQ:GLUE) and Emergent Biosolutions (NYSE:EBS)EBS · tickerreport.com · 16 Oct 2026
0 headlines in the last 90 days name Coleen Glessner; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.